May 6, 2021

American CryoStem Executes LOI with Advanced Regenerative Associates to Conduct Wound Healing Clinical Study

American CryoStem Corporation (OTC PINK: CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced today, that it has signed a Letter of Intent (LOI) with Advanced Regenerative Associates, LLC (“ARA”) of Tinton Falls, NJ for the development of a cell-based wound covering treatment for non-healing wounds, skin ulcers, and limb ischemia associated with type II diabetes, burns, and other systemic conditions.
March 11, 2021

American CryoStem Announces Patient Biomaterial Processing for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial

American CryoStem Corporation (OTC: CRYO) a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has begun processing patient's adipose tissue and culturing mesenchymal stem cells (ATCell™), for use in its FDA approved IND Phase I Clinical Trial.
February 25, 2021
American CryoStem starts Post-Concussion Syndrome clinical trials

American CryoStem and BioTherapeutic Labs Corp. Enter into R&D, Collaboration and Marketing Agreement

American CryoStem Corporation (OTC: CRYO), a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies, announced today that it has entered into an Agreement with BioTherapeutic Labs Corp. (BTL) an FDA registered Umbilical Cord Tissue Manufacturing Company headquartered in Boca Raton, Florida.
January 6, 2021

American CryoStem Enters into a Cooperative Research and Development Agreement (CRADA) to Develop Standardized Treatment Protocols

American CryoStem Corporation (OTC: CRYO), a clinical stage biotechnology Company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) authorized by published code 15 U.S.C. 3710a of US Title 15 Commerce and Trade. (https://www.disa.mil/about/cto/crada-process-overview) The Collaborative work will be conducted at the Biomedical Research Laboratory in Bethesda, Maryland.
December 1, 2020
American CryoStem starts Post-Concussion Syndrome clinical trials

American CryoStem Announces Patient Recruitment and Additional Sub-Investigator for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial

American CryoStem Corporation Issues Shareholder LetterEATONTOWN, NJ / ACCESSWIRE / December 1, 2020 / American CryoStem Corporation (OTC PINK: CRYO) a clinical stage biotechnology company, global […]
September 23, 2020

American CryoStem Announces: FDA has cleared its Investigational New Drug (IND) for Post-Concussion Syndrome for Phase I Clinical Trial

American CryoStem Corporation Issues Shareholder LetterEATONTOWN, NJ / ACCESSWIRE / September 23, 2020 / American CryoStem Corporation (OTC PINK:CRYO) is a clinical stage biotechnology company, global licensor, […]
June 29, 2020

American CryoStem Announces the Conversion of Debenture into Equity and Sale into the Market

American CryoStem Corporation Issues Shareholder LetterThe debt issuance has been executed in accordance with the terms of the Debenture contained in the Company\’s 10-Q through the […]
April 2, 2020
American CryoStem starts Post-Concussion Syndrome clinical trials

American CryoStem to Develop ATCELL™ Clinical Study for Duchene Muscular Dystrophy with RACEMD

American CryoStem Corporation Issues Shareholder LetterAmerican CryoStem to Develop ATCELL™ Clinical Study for Duchene Muscular Dystrophy with RACEMD April 1, 2020 EATONTOWN, NJ / ACCESSWIRE / April […]
December 5, 2019

American CryoStem Corporation Issues Shareholder Letter

American CryoStem Corporation Issues Shareholder LetterEATONTOWN, NJ / ACCESSWIRE / December 5, 2019 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer, and global […]